MyKnight wrote: Does are the top company on the world dealing with GVHD, they will loose this market if they don't have an agreement with Kaly...

As I was talking to rob this summer, he  set at a minimum price of 5 Billions, I though that was agressive ...  I don't anymore once we look at which company we're dealing with, and the market that kaly will take from them...

This is only speculation from my part but I belive that they have the licence set up with one of does, and after they had a chance of trying it out in Europe, they would buy them at the Price that Rob ask ... 

And you can see that buying kaly at 5 Billions would be easy and a great deal for them...

Bristol-Myers Squibb (161 Billions Market Cap)
Abbott (155 Billions MC)
AbbVie (132 Billions)
Allergan (63 Billions)
Anterogen(334 Billions)
Astellas Pharma (3 450 Billions)
Athersys (189 Billions)
Eli Lilly (127 Billions)
GlaxoSmithKline (89 Billions)
Glenmark (96 Billions)
Sanofi (115 Billions)
Shire(54 Billions)

Soon ....